Valuation : Gilead Sciences, Inc.

Market Cap 181B 273,412B 156B 146B 133B 251B 17,264B 252B 1,731B 676B 8,715B 678B 663B 28,897B P/E 2026 *
-44.5x
P/E 2027 * 18.2x
Enterprise Value 197B 298,757B 170B 159B 146B 274B 18,865B 275B 1,892B 738B 9,523B 741B 725B 31,576B EV / Sales 2026 *
6.43x
EV / Sales 2027 * 5.8x
Free-Float
99.88%
Yield 2026 *
2.26%
Yield 2027 * 2.33%
1 day-1.85%
1 week+0.47%
Current month+13.61%
1 month+14.39%
3 months+17.23%
6 months+6.47%
Current year+24.68%
1 week 58,175
Extreme 58175
59,975
1 month 50,825
Extreme 50825
59,975
Current year 44,320
Extreme 44320
59,975
1 year 36,450
Extreme 36450
59,975
3 years 13,722
Extreme 13722
59,975
5 years 2,682.5
Extreme 2682.5
59,975
10 years 656.5
Extreme 656.5
59,975
Manager TitleAgeSince
Chief Executive Officer 61 28/02/2019
Director of Finance/CFO 56 31/10/2019
Compliance Officer - 17/12/2025
Director TitleAgeSince
Director/Board Member 58 18/08/2016
Director/Board Member 73 31/12/2017
Director/Board Member 72 08/05/2018
Change 5-day change 1-year change 3-year change Capi.($)
-1.85%+0.47% - - 181B
-0.13%-6.44%+60.34%+114.35% 1,047B
+0.85%-0.81%+51.29%+63.71% 646B
-1.03%-3.58%+21.43%+72.25% 451B
-0.77%-3.89%+36.82%+36.77% 355B
-0.18%-2.48%+21.75%+38.42% 291B
-1.19%-2.21%+1.53%+11.51% 252B
-1.05%-1.57%+50.30%+67.68% 234B
-1.18%-2.41%-20.01%-54.15% 203B
-2.14%-0.30%+28.95%+87.59% 181B
Average -0.87%-2.68%+28.04%+48.68% 406.59B
Weighted average by Cap. -0.49%-3.46%+37.90%+65.93%

Financials

2026 *2027 *
Net sales 30.69B 46,456B 26.45B 24.8B 22.64B 42.64B 2,933B 42.78B 294B 115B 1,481B 115B 113B 4,910B 32.7B 49,487B 28.17B 26.42B 24.11B 45.43B 3,125B 45.57B 313B 122B 1,577B 123B 120B 5,230B
Net income -4.27B -6,470B -3.68B -3.45B -3.15B -5.94B -409B -5.96B -40.97B -15.99B -206B -16.05B -15.7B -684B 10.28B 15,552B 8.85B 8.3B 7.58B 14.28B 982B 14.32B 98.49B 38.43B 496B 38.58B 37.74B 1,644B
Net Debt 16.75B 25,346B 14.43B 13.53B 12.35B 23.27B 1,600B 23.34B 161B 62.63B 808B 62.87B 61.5B 2,679B 9.12B 13,811B 7.86B 7.37B 6.73B 12.68B 872B 12.72B 87.46B 34.12B 440B 34.26B 33.51B 1,460B
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
28/08/26 ARS 58,425.00 -1.85% 1,882
27/08/26 ARS 59,525.00 0.00% 334
26/08/26 ARS 59,525.00 +0.04% 540
25/08/26 ARS 59,500.00 +1.54% 480
24/08/26 ARS 58,600.00 +0.77% 1,467
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
145.68USD
Average target price
157.41USD
Spread / Average Target
+8.05%

Quarterly revenue - Rate of surprise